Haematology 2018

Is it possible to reverse the adverse outcomes of ABC DLBCL with bortezomib?...no

• The nuclear factor-kB (NF-kB) pathway is constitutively activated in ABC DLBCL 1 • The proteasome inhibitor bortezomib is a potent inhibitor of NF-ĸB 2 ; may therefore have specific utility in non-GCB DLBCL and overcoming the negative prognosis associated with non-GCB phenotype 3,4

Ruan J et al. J Clin Oncol. 2011;29(6):690-697

1 Davis RE et al. J Exp Med. 2001;194(12):1861-1874. 2 Bu R et al. Leuk Lymphoma. 2014; 55(2):415-424. 3 Ruan J et al. J Clin Oncol. 2011;29(6):690-697. 4 Dunleavy et al. Blood. 2009; 113(24):6069-6076.

53